Literature DB >> 12828690

Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: comparison of efficacy with fluences immediately above and below the purpura threshold.

Murad Alam1, Jeffrey S Dover, Kenneth A Arndt.   

Abstract

BACKGROUND: : Pulsed-dye laser treatment has been shown to be highly effective for the treatment of facial telangiectasia. Posttreatment purpura after such treatment has limited patient acceptance of the procedure.
OBJECTIVE: : To determine whether purpura-free treatment with recently introduced variable-pulsed pulsed-dye lasers can effectively reduce facial telangiectasia.
METHODS: : This was a prospective, randomized, controlled, nonblinded trial. Eleven patients received variable-pulse pulsed-dye laser treatment with and without induction of purpura. Telangiectasia were graded on a "telangiectasia density scale," on which a 1 signified extremely fine, sparsely distributed telangiectasia, and 5 referred to thick, ropelike telangiectasia covering the affected area. For each subject, two areas on either side of the facial midline with equivalent telangiectasia density ratings were randomized to the purpura and purpura-free treatment groups, respectively. All treatments used a 7-mm spot size and a 10-ms pulse duration. The fluence associated with the purpura threshold for each patient was determined in test areas. Purpura-free treatment entailed a fluence 1.0 J/cm2 less than the purpura threshold, and purpura-level treatment entailed a fluence 0.5 J/cm2 greater than the threshold.
RESULTS: : Six weeks after a single purpura-free treatment, mean telangiectasia ratings were reduced from 2.7 to 2.4. Purpura-level treatments resulted in a decrease to 1.4 from the same baseline. Thicker, denser telangiectasia appeared to benefit more from purpura-level treatment (a mean telangiectasia density scale reduction of 1.7) than finer, sparser telangiectasia (a mean reduction of 0.8). In 81% of cases, both investigators and patients rated the side treated with purpura as undergoing a greater reduction in telangiectasia density.
CONCLUSION: : Although facial telangiectasia do improve after a single purpura-free treatment with the variable-pulse pulsed-dye laser, they improve more after purpura is induced. Purpura-free and purpura-level treatments may be close to equivalent for treating fine telangiectasia, but purpura-level treatments have a distinct advantage for treating thicker telangiectasia. Significantly, the variable-pulse pulsed-dye laser offers patients the option of effective treatment of some telangiectasia without bruising.

Entities:  

Mesh:

Year:  2003        PMID: 12828690     DOI: 10.1046/j.1524-4725.2003.29181.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  Current concepts: laser treatment of adult vascular lesions.

Authors:  Tomi L Wall
Journal:  Semin Plast Surg       Date:  2007-08       Impact factor: 2.314

2.  [Segmental Darier disease : treatment with pulsed dye laser].

Authors:  L Schmitt; S Roos; C Raulin; S Karsai
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

Review 3.  Laser and light-based therapies in the management of rosacea: an updated systematic review.

Authors:  Husein Husein-ElAhmed; Martin Steinhoff
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

4.  Update on the management of rosacea.

Authors:  Allison P Weinkle; Vladyslava Doktor; Jason Emer
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-07

Review 5.  Laser treatment of medical skin disease in women.

Authors:  C LaRosa; A Chiaravalloti; S Jinna; W Berger; J Finch
Journal:  Int J Womens Dermatol       Date:  2017-07-21

6.  Skin anti-aging strategies.

Authors:  Ruta Ganceviciene; Aikaterini I Liakou; Athanasios Theodoridis; Evgenia Makrantonaki; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2012-07-01

Review 7.  Light-Based Devices for the Treatment of Facial Erythema and Telangiectasia.

Authors:  Vani Yepuri; Anant D Patil; Klaus Fritz; Carmen Salavastru; George Kroumpouzos; Steven Paul Nisticò; Domenico Piccolo; Ahmed Sadek; Ashraf Badawi; Martin Kassir; Michael H Gold; Stephan Große-Büning; Stephan Grabbe; Mohamad Goldust
Journal:  Dermatol Ther (Heidelb)       Date:  2021-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.